Mechanisms and strategies to overcome resistance to enfortumab vedotin in bladder cancer.

被引：0
|
作者：
Chang, Kevin [1 ]
Lodha, Roshan [2 ]
Delavan, Henry M. [3 ]
Winebaum, Jenna [3 ]
Porten, Sima P. [1 ]
Feng, Felix Y. [3 ]
Chu, Carissa E. [1 ]
Chou, Jonathan
机构：
[1] Univ Calif San Francisco, San Francisco, CA USA
[2] Cleveland Clin, Lerner Coll Med, Cleveland Hts, OH USA
[3] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期
关键词：
3282-646-2719; 613-615-646-4685-2424; 283-183-138-226-9326; 283-183-138-11076; 261-374-2500-10670-7136; 5; 3; 2; 3224; 1876; 1; 38092-33344; 38092-27054;
D O I：
10.1200/JCO.2024.42.4_suppl.690
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：690 / 690
页数：1
相关论文
共 50 条
  • [1] MECHANISMS AND STRATEGIES TO OVERCOME RESISTANCE TO ENFORTUMAB VEDOTIN IN BLADDER CANCER
    Kevin, Chang
    Henry, Delavan
    Sima, Porten
    Felix, Feng
    Jonathan, Chou
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2024, 42 : S28 - S29
  • [2] A new era for bladder cancer: Enfortumab vedotin and pembrolizumab milestone approval
    Zameer, Ushna
    Shaikh, Wajiha
    TUMORI JOURNAL, 2024, 110 (04): : 295 - 296
  • [3] The role of enfortumab vedotin and sacituzumab govitecan in treatment of advanced bladder cancer
    Hanna, Kirollos S.
    Larson, Samantha
    Nguyen, Jenny
    Boudreau, Jenna
    Bulin, Jennifer
    Rolf, Mallory
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2022, 79 (08) : 629 - 635
  • [4] Enfortumab Vedotin in urothelial cancer
    Alt, Marie
    Stecca, Carlos
    Tobin, Swanee
    Jiang, Di Maria
    Sridhar, Srikala S.
    THERAPEUTIC ADVANCES IN UROLOGY, 2020, 12
  • [5] Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
    Haynes, Jennifer
    Manogaran, Prasath
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [6] Mechanisms and strategies to overcome multiple drug resistance in cancer
    Ozben, Tomris
    FEBS LETTERS, 2006, 580 (12): : 2903 - 2909
  • [7] Activity of Enfortumab Vedotin and Sacituzumab Govitecan with Radiation in Preclinical Models of Bladder Cancer
    Zhou, Yuzhen
    D'Andrea, Vincent D.
    Shanmugam, Surish P.
    Stelter, Isabella
    Stormoen, Dag R.
    Chroneos, Rea
    Hanlon, Timothy
    Epstein, Ilana
    Bekele, Raie T.
    Anderson, William J.
    Carvalho, Filipe F. L.
    Bellmunt, Joaquim
    Mouw, Kent W.
    EUROPEAN UROLOGY, 2024, 86 (01)
  • [8] Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
    Coley, Helen M.
    CANCER TREATMENT REVIEWS, 2008, 34 (04) : 378 - 390
  • [9] Synergistic effect of combination of pemigatinib with enfortumab vedotin (EV) in human bladder cancer models
    Hess, Rodrigo A.
    Truong, Lisa
    Chadderton, Antony
    Frascella, Michelle
    Hall, Leslie
    Koblish, Holly
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [10] Mechanisms of endocrine resistance and strategies to overcome
    Tesch, H.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 14 - 14
12345